Efficacy of New Antiepileptic Drugs

Dieter Schmidt, MD
Epilepsy Research Group, Berlin, Germany
Address correspondence to Dieter Schmidt, MD, Epilepsy Research Group, Berlin, Goethestr. 5, D-14163 Berlin, Germany.
E-mail: dbschmidt@t-online.de

Regarding efficacy of new antiepileptic drugs (AEDs) for seizure control, there are three important clinical questions. How effective are new AEDs when corrected for the efficacy of placebo? And even more important: How do new AEDs fare in terms of seizure remission compared with established agents? And finally: Have patients seizure-free on new AEDs a better chance for lasting remission after withdrawal versus those withdrawing from older agents? The answers raise concerns. Although add-on therapy with marketed new AEDs is more effective than placebo, as expected, the treatment difference for becoming seizure-free is disappointingly small (6%; 95% CI: 4–8%; z = 6.47; p < 0.001). Although many, but not all, new AEDs have comparable efficacy to old standard drugs in well-controlled trials, none of the new AEDs is superior to old drugs in terms of seizure remission. So far, we have no antiepileptogenic treatments that prevent the development of epilepsy or modify its detrimental course. The sobering results suggest the need for novel experimental and clinical strategies for the development of more effective new AEDs that interrupt ictogenesis more effectively and prevent or abort epileptogenesis. Ideally, we need new drugs that block both ictogenesis and epileptogenesis, resulting in complete cure of epilepsy.

Although a large number of new antiepileptic drugs (AEDs) that suppress or prevent seizures are now available, about 30 to 40 percent of the patients, children as well as adults, remain resistant to drug treatment (1). The situation is even worse for a range of severe epilepsy syndromes of infancy and adolescence. So far, we have no antiepileptogenic treatments that prevent the development of epilepsy or modify its detrimental course (2). The introduction of each new AED into the market raises valid expectations in patients and physicians for more effective treatment of epilepsy. Although safety, tolerability, and lack of interactions are important, better efficacy is a crucial feature for a new AED. This brief review is limited to a discussion of the efficacy of new versus old AEDs. In that respect, three questions are of particular clinical interest: How effective are new AEDs when corrected for the efficacy of placebo? And even more relevant: Are new AEDs more often leading to seizure remission compared with established agents? And finally: Can more patients maintain seizure remission after withdrawal of new AEDs compared with withdrawal of older agents? The following brief overview, which is not a comprehensive literature review, outlines the available evidence on the efficacy of modern AEDs based on randomized controlled trials of marketed modern AEDs.

Question 1: How effective are new AEDs when corrected for efficacy of placebo: Add-on?
Although adjunctive treatment with new AEDs is standard care in treatment resistant epilepsy, it is less well known how much of the effect can be directly attributed to the AEDs and how much of the beneficial changes are due to placebo. A recent meta-analysis determined the placebo-corrected net efficacy of adjunctive treatment with modern AEDs on the market for treatment resistant epilepsy in more than 11,000 adults and children (3). The overall weighted pooled risk difference in favor of AEDs over placebo was 6% (95% CI: 4–8%; z = 6.47; p < 0.001) for seizure freedom and 21% (95% CI: 19–24%; z = 17.13; p < 0.001) for 50% seizure reduction (3). Although the presence of moderate heterogeneity between studies was a limitation of the analysis, the study indicated that the placebo-corrected efficacy of adjunctive treatment with modern AEDs is disappointingly small and suggested that better strategies for finding drugs are needed for treatment resistant epilepsy (3).

How effective are new AEDs when corrected for efficacy of placebo: Monotherapy?
Monotherapy trials have raised some ethical concerns, as the designs require patients with known epilepsy to either be undertreated or treated with placebo. A few studies have been performed, but there is a paucity of data in this area. There were no data for lamotrigine (LTG), levetiracetam (LEV), or topiramate (TPM) monotherapy versus placebo, and only two trials compared oxcarbazepine (OXC) with placebo (4). Data were only available for proportion of seizure-free participants and the time to event outcomes (first seizure and exit/withdrawal). Both OXC trials were short term and included only patients...
with partial seizures (treatment resistant in one trial and newly
diagnosed patient in the other (4)). The trial of patients with
refractory partial seizures only included treatment over 10
days and was carried out in patients undergoing evaluation
for possible surgery. Therefore the findings of this trial have
limited applicability to the general population of patients with
partial seizures (4). The evidence to support OXC in favor of
placebo was also very limited. The data come from small trials
conducted over short treatment durations and one trial relates
specifically to patients undergoing evaluation for surgery,
limiting its applicability. Considering all of these factors, the
statistically significant differences observed in the proportion
of seizure-free participants in favor of OXC versus placebo
should be regarded with caution (4). There is no evidence on
which to base an assessment of LEV, LTG, and TPM (4).

**Question 2: How do AEDs fare in terms of seizure remission compared to established AEDs?**

**Treatment of Idiopathic Generalized Epilepsy**
The efficacy of new versus old AEDs for the treatment of idiopathic
generalized epilepsy was studied in Arm A of the
SANAD trial, which compared valproate (VPA), LTG, and TPM
for treatment of mostly untreated epilepsy in an unmasked
randomized design (5). SANAD was designed to assess
whether any of the new AEDs available at the time (LTG, TPM)
should become first-line treatment and thereby replace VPA
as the existing first-line agent (5). The result was that VPA was
more efficacious than LTG and similar in efficacy to TPM for
the subgroup of patients with idiopathic generalized epilepsy (5).
A multicenter double-blind randomized trial compared treat-
ment with ethosuximide (ESM), LTG, or VPA in 453 children
with new-onset absence epilepsy of childhood (6). After 16
weeks of therapy, the freedom-from-failure rates for ESM and
VPA were similar (53% and 58%), but for both the rates were
higher than for LTG (29%; p < 0.001 for both comparisons).

**Treatment of Focal Epilepsy**
Arm B of the SANAD trial was designed as a pragmatic trial to
assess whether any of the new AEDs (LTG, gabapentin [GBP],
TPM, or OXC) should become first-line treatment and thereby
replace the existing first-line agent carbamazepine (CBZ) (5).
Based on efficacy criteria alone, and only those are discussed
here, none of the new AEDs were superior in efficacy to CBZ
although LTG and OXC were considered to be noninferior in
efficacy, while CBZ was reported to be more efficacious
compared with GBP and TPM (5). Levetiracetam (LEV), which
entered the market later, could not be studied in SANAD.
However, a well-controlled noninferiority trial has shown that,
at per-protocol analysis, 73.0% of patients randomized to LEV
and 72.8% receiving controlled-release CBZ were seizure free
at the last evaluated dose (adjusted absolute difference 0.2%;
95% CI: −7.8–8.2%) for at least 6 months indicating equivalent
seizure remission for LEV versus slow-release CBZ (7).
Although the incidence of epilepsy in those 65 years and
older is increasing over the last decades (8), there are only
a few studies comparing new versus old AEDs for treatment
of epilepsy in the elderly. In a 24-week double-blind trial,
LTG and CBZ were compared in 150 patients 65 years and
older with newly diagnosed epilepsy (9). Here we primarily
address the efficacy results. Forty patients on LTG (39%)
remained seizure-free during the final 16 weeks and did
not discontinue drug treatment compared with 10 (21%)
patients taking CBZ (p = 0.027). In addition, the authors
determined the proportion of patients who remained
seizure-free as a proportion of those patients remaining in
the study. No differences were detected between treatments
on this outcome measure. The hazard ratio was 0.86 (95% CI:
0.42–1.77; p = 0.68). The wide confidence intervals indi-
cate that the study had a low power to detect a difference
between treatments in terms of this outcome measure (9).
In this study, retention on treatment at the end of the trial
was significantly higher in patients treated with LTG than in
those treated with CBZ (71% vs 42%, respectively), the differ-
ence being ascribed primarily to lower rates of withdrawal
because of adverse events in the LTG group. More recently,
593 elderly subjects with previously untreated or under-
treated seizures were randomized in a study to LTG, CBZ, or
GBP (10). Retention in the trial at 12 months was significant-
ly greater in the groups allocated to LTG and GBP (56% and
49%, respectively) than in the group allocated to CBZ (36%).
However, there were no significant differences in seizure-
free rate at 12 months (10).

Although these studies suggest that new AEDs may offer
tolerability advantages over CBZ for the treatment of epilepsy
in old age, both studies used immediate-release rather than
sustained-release CBZ, and at least in the U.S. trial the initial
target dosages for LTG and CBZ were relatively high compared
with those reported to be optimal in most patients (9). The
comparative effectiveness, efficacy, and tolerability of LTG
and sustained-release CBZ in the treatment of newly diag-
nosed focal epilepsy in the elderly was assessed in a 40-week,
multicenter double-blind, parallel group design (11). In the LTG
group, 68 patients (73%) completed the 40-week study period
compared with 61 (67%) in the CBZ group, a nonsignificant dif-
fERENCE. The number of subjects who completed the 40-week
period and were seizure-free in the last 20 weeks was 48 (52%)
in the LTG group and 52 (57%) in the CBZ group. A total of
110 subjects did not have any seizure during the study, and of
these 50 (54% of the intention-to-treat [ITT] cohort) had been
 randomized to LTG and 60 (66%) had been randomized to CBZ.
No significant differences between treatments were identified
by the time to first seizure analysis in the intention-to-treat
population. In the per-protocol population, however, time to
first seizure was significantly longer in the CBZ group than in
the LTG group (11). In summary, LTG and CBZ showed compa-
able effectiveness as measured by retention, with a trend for
higher seizure-free rates for CBZ and better tolerability for LTG.
 Differences in outcome compared with previous trials may be
related to different dosing rates and use of a sustained-release
formulation for CBZ (11).

**Question 3: Do patients on new AEDs have a better chance of maintaining remission after withdrawal of AEDs than patients on older AEDs?**

Approximately two-thirds of patients with new-onset epi-
lepsy will become seizure-free when treated with new AEDs,
as discussed previously. In a proportion of these patients
who maintain prolonged remission over several years, complete withdrawal of AED treatment is a worthwhile consideration. Unfortunately, we currently have no information from randomized withdrawal trials to determine the risk–benefit balance of stopping new AEDs in seizure-free patients. A lower rate of relapse after withdrawal of new versus old AEDs would be a clinically important efficacy benefit in favor of new drugs.

Conclusions

Although the introduction of new AEDs brought substantial advantages over old AEDs, in particular through the absence of severe hypersensitivity reactions and of detrimental drug interactions mediated by enzyme-induction in some new AEDs, we found no evidence that any new AED was superior to old AEDs such as CBZ and VPA in efficacy in well-controlled trials of recent-onset epilepsy. This is cause for major concern, given the unimproved proportion of patients with drug-resistant epilepsy. However, several new AEDs such as LEV, LTG, and OXC have been shown to be noninferior in efficacy to CBZ. Moreover, GBP was shown to be less efficacious versus CBZ and LTG in mostly untreated partial epilepsy and LTG was shown to be less efficacious versus VPA and ESM for previously untreated childhood absence epilepsy.

References


Highlights

There is a need for the following:

- More efficacious new AEDs for suppression or prevention of seizures to lower the incidence of drug-resistant epilepsy
- More direct comparisons of newer versus newer and newer versus older AEDs within clinical trials, both for monotherapy and adjunctive therapy
- Good-quality trials with appropriate designs, ideally adopting the International League Against Epilepsy guidelines on the design of trials, particularly with regard to length of follow-up
- Randomized withdrawal trials to determine the risk–benefit balance of stopping new versus old AEDs in seizure-free patients
- Development of antiepileptogenic agents to prevent epilepsy in people at risk and to attenuate the detrimental course of epilepsy

Efficacy of New Antiepileptic Drugs
Instructions
The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

1. Identifying information.
   Enter your full name. If you are NOT the main contributing author, please check the box “no” and enter the name of the main contributing author in the space that appears. Provide the requested manuscript information.

2. The work under consideration for publication.
   This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking “No” means that you did the work without receiving any financial support from any third party – that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check “Yes”. Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

3. Relevant financial activities outside the submitted work.
   This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. For example, if your article is about testing an epidermal growth factor receptor (DGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

   Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work’s sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

   For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Other relationships
   Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.
American Epilepsy Society

Epilepsy Currents Journal
Disclosure of Potential Conflicts of Interest

Section #1 Identifying Information

1. Today’s Date: DEC15, 2010

2. First Name: Dieter Last Name: Schmidt Degree: MD

3. Are you the Main Assigned Author? Yes No
   If no, enter your name as co-author

4. Manuscript/Article Title: Efficacy of new antiepileptic drugs

5. Journal Issue you are submitting for: Jan 2011

Section #2 The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Grant</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>Add</td>
</tr>
<tr>
<td>2. Consulting fee or honorarium</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>3. Support for travel to meetings for the study or other purposes</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>Add</td>
</tr>
<tr>
<td>4. Fees for participating in review activities such as data monitoring boards, statistical analysis, end point committees, and the like</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>Add</td>
</tr>
<tr>
<td>5. Payment for writing or reviewing the manuscript</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>Add</td>
</tr>
<tr>
<td>6. Provision of writing assistance, medicines, equipment, or administrative support.</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>Add</td>
</tr>
<tr>
<td>7. Other</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>Add</td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts on this study.
** Use this section to provide any needed explanation.
**Section #3 Relevant financial activities outside the submitted work.**
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add” box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type of relationship (in alphabetical order)</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comment s**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Board membership</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>2. Consultancy</td>
<td>X</td>
<td></td>
<td></td>
<td>UCB, Lundbeck, Desitin, Grünenthal, Novartis, and GSK</td>
<td>X</td>
</tr>
<tr>
<td>3. Employment</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>4. Expert testimony</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>5. Grants/grants pending</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>6. Payment for lectures including service on speakers bureaus</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>7. Payment for manuscript preparation</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>8. Patents (planned, pending or issued)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>9. Royalties</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>10. Payment for development of educational presentations</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>11. Stock/stock options</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>12. Travel/accommodations/meeting expenses unrelated to activities listed,**</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>13. Other (err on the side of full disclosure)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts.
** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

**Section #4 Other relationships**
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

___ No other relationships/conditions/circumstances that present a potential conflict of interest.
___ Yes, the following relationships/conditions/circumstances are present:
Thank you for your assistance.